Short-term mortality and prognostic factors related to status epilepticus

Mortalidade a curto prazo e fatores prognósticos de status epilepticus

Fernando Gustavo Stelzer, Guilherme de Oliveira Bustamante, Heidi Sonder, America Ceiki Sakamoto, Regina Maria França Fernandes

ABSTRACT

Objective: Status epilepticus (SE) is associated with significant morbidity and mortality, and there is some controversy concerning predictive indicators of outcome. Our main goal was to determine mortality and to identify factors associated with SE prognosis. Method: This prospective study in a tertiary-care university hospital, included 105 patients with epileptic seizures lasting more than 30 minutes. Mortality was defined as death during hospital admission. Results: The case-fatality rate was 36.2%, which was higher than in previous studies. In univariate analysis, mortality was associated with age, previous epilepsy, complex focal seizures; etiology, recurrence, and refractoriness of SE; clinical complications, and focal SE. In multivariate analysis, mortality was associated only with presence of clinical complications. Conclusions: Mortality associated with SE was higher than reported in previous studies, and was not related to age, specific etiology, or SE duration. In multivariate analysis, mortality was independently related to occurrence of medical complications.

Keywords: status epilepticus, epilepsy, mortality, prognosis.

University of São Paulo de Ribeirão Preto, Hospital das Clínicas, Ribeirão Preto SP, Brazil.
Correspondence: Fernando Gustavo Stelzer; Avenida Independência, 900/apto 805; 90035-072 Porto Alegre RS, Brasil; E-mail: fgst@uol.com.br
Conflict of interest: There is no conflict of interest to declare.
Received 13 January 2015; Received in final form 8 March 2015; Accepted 30 March 2015.
METHOD

We retrospectively studied all 105 patients older than 1 month of age who were diagnosed with SE and admitted to the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP), a tertiary-care hospital, between February and December 2000. SE was defined as a clinical or electrographic seizure lasting more than 30 minutes or recurrent seizures without full recovery of consciousness for 30 minutes or more. Serial 18- or 21-channel electroencephalograms (EEGs) (Nihon Kohden, Japan), were obtained from all patients following the 10-20 International System of electrode placement. After discharge or death, medical records were reviewed, including demographic data, medical history, prior history of epilepsy, SE classification, seizure duration, SE etiology, EEG patterns, treatment, response to treatment, and prognosis during the hospital stay. There was no follow-up after discharge.

The sample was divided into two groups by prognosis. Those in group I survived until hospital discharge, and those in group II died while inpatients. Patients younger than 1 month of age and patients diagnosed with pseudo-status epilepticus were excluded from the study.

Patients were divided into three categories based on clinical semiology following the Classification of Epileptic Seizures (i.e., focal, secondarily generalized, and generalized SE). Clinical presentation was described as generalized tonic-clonic seizure (GTCS), focal complex seizure (FCS), focal simple seizure (FSS), absence seizure, tonic seizure, epileptic spasms, delirium, or confusional state. SE was further characterized as convulsive or nonconvulsive by semiology.

Refractory SE was defined as absence of clinical and/or EEG control if seizures occurred after use of first and second line-drugs (e.g., IV diazepam, phenytoin, or phenobarbital). Third-line treatment included IV continuous midazolam and/or thiopentone. Refractory patients were given ventilator support when necessary.

SE etiology was classified as follows:

- Acute symptomatic: SE occurring during within 7 days of an acute disease, such as CNS infection, brain trauma, cerebrovascular disease, toxic or metabolic insulins.
- Febrile: SE in a previously neurologically healthy child where the only provocative factor was a febrile disease with axillary temperature ≥ 38°C and not related to CNS infection.
- Progressive symptomatic: SE related to progressive diseases such as brain neoplasms or neurodegenerative disorders including innate metabolic errors.
- Remote symptomatic: SE in an individual with prior (> 7 days) neurological disease, including cerebrovascular disorders or brain trauma, in the absence of acute insult.
- Acute on remote symptomatic: SE occurring during an acute neurological insult (e.g., fever, toxic or metabolic insults, alcohol or drug withdrawal), in an individual with a remote symptomatic etiology.

- Previous epilepsy with low antiepileptic drug (AED) levels or AED withdrawal: SE occurring in a previously epileptic individual with documented low AED level and/or history of AED noncompliance or change in therapy.
- Cryptogenic: SE occurring in the absence of a known acute or remote etiologic factor.

SE groups were stratified by etiology and refractoriness to SE only (febrile, cryptogenic, low AED level, acute on remote symptomatic, and symptomatic) and SE plus (acute symptomatic, progressive, and refractory SE of any etiology).

Ictal EEG pattern evolution was evaluated in serial EEG recordings and classified as discrete seizures (DS), merging seizures (MS), continuous ictal discharge (CD), CD with flat periods (CDF), and periodic lateralized epileptic discharges (PLED) as described by Treiman. The initial ictal pattern of each patient was analyzed.

Patients were treated according to the existing institutional protocol, which, besides support measures, consisted of (1) diazepam IV (10-20 mg bolus); (2) phenytoin IV (10-30 mg/kg infused at maximum dose of 50 mg/min); (3) phenobarbital IV (20-30 mg/kg). Following first- and second-line treatments, the options included (1) midazolam or (2) thiopental IV continuous.

Statistical analysis

Continuous variables were compared using the Mann-Whitney test and categorical variables were compared using Pearson’s chi-square. Odds ratios (ORs) were determined by logistic regression and reported with 95% confidence intervals (CIs). Statistical significance was established at the 0.05 level. Multivariate analysis was used to determine independent mortality risk factors. All statistical analyses was done using SSPS for Windows, version 10 (SSPS, Inc., Chicago, USA).

RESULTS

During the study period, 105 SE patients were admitted to HCFMRP-USP. Their mean age was 30.0 ± 26.8 years; 42 patients (40%) were women, and the male-female ratio was 1.5:1. The mortality rate was 36.2%, with 38 patients dying during their hospital stay. Following clinical or ECG criteria, SE was not stopped until death in 10 patients (9.5%). Overall, there were 125 SE episodes.

Univariate analysis

Table 1 summarizes the findings of univariate analysis. SE survivors were younger in group I (mean age = 24.9 ± 23.9 years) than in group II (39.3 ± 29.3 years; Z = 2.14, p = 0.032). The mortality rate was higher in the elderly (≥ 65, 64.7%) than in children (< 12 years of age, 25.7%), and adults (34.7%). There was no difference in gender-related mortality (33.3% in men and 40.4% in women). Fifty-five patients (52.4%) had a history of prior epilepsy, and they had a mortality rate of 18.2%.
compared with 56.0% in those without a history of epilepsy (p < 0.001). The most frequent seizure type was FCS (37.1%), followed in descending order by GTCS (28.6%) and FCC evolving to GTCS (14.3%). FCC had the highest mortality rate (51.3%; p = 0.015). Compared with other seizure types, GTCS had a lower mortality rate (20%; p = 0.033). There were no significant differences in mortality among other seizure types. No patients with absence seizure died. Convulsive SE predominated (86.7%) in this sample, and there was no difference in the mortality rates of patients with convulsive (36.3%) and nonconvulsive (35.7%) SE.

The SE etiologies of the study patients are shown in Table 1. Acute symptomatic SE etiology predominated (32.4%), followed by acute on remote symptomatic SE (19.0%), AED noncompliance in previously epileptic patients (19.0%), remote symptomatic SE (16.2%), progressive symptomatic SE (7.6%), cryptogenic SE (3.6%), and febrile SE (1.9%). The mortality rate was significantly higher in acute symptomatic SE (53%; p = 0.015), and lower in the AED noncompliance group (5%; p = 0.011).

As for SE classification (Table 1), focal SE (46.7%) was the most frequent, followed by secondary generalized SE (42.9%), and generalized SE (10.5%). Mortality was the highest in those with focal SE (49%; p = 0.012). SE recurrence in the same hospital admission was observed in 11.4% of patients, and the mortality was higher in this group (66.7% versus 32.2%; p = 0.020). Refractory SE was diagnosed in 36.2% of patients, and they had a higher mortality rate (57.9 versus 23.8%; p = 0.001).

Fifty-one patients (48.6%) were included in the SE-only group and 56 (51.4%) in the SE-plus group. Mortality was greater in the SE-plus than in the SE-only group (55.4% versus 14.3%; p < 0.001). Ictal EEG patterns were identified in 55.2%
of patients, with PLED having a significantly higher mortality rate (60%; OR = 3.16; p = 0.045). As PLED predominated among elderly patients, there was no difference in ictal pattern-related mortality when the analysis was controlled for age.

Severe clinical complications occurred in 67.6%, of patients, and 48 (45.7%) had more than one complication (Table 2). The most common complications were respiratory failure with mechanical ventilation, arterial hypotension, and pneumonia. Other complications, such as cardiac arrhythmias, and urinary tract infections, were rare in this sample. Clinical complications were more frequent among refractory SE individuals (97.2 versus 52.2%; p < 0.0001) and in the SE plus group (49.0% versus 83.9%; p < 0.0001; Table 3). Mortality was higher in individuals with clinical complications (50.7 versus 5.9%; p < 0.001).

**Multivariate analysis**

In multivariate analysis, only the presence of medical complications was related to a higher mortality rate (p = 0.013; OR = 11.8; CI = 1.7-82.1).

**DISCUSSION**

Comparing mortality related to SE in different study populations is difficult because of differences in methodology, definition (seizure duration of 5 versus 30 minutes), study design (prospective versus retrospective), population (pediatric versus adults, community versus university hospital), treatment (lack of medication or medical facilities in different countries), and follow-up period (short- versus long-term follow-up).

The short-term mortality rate in our sample (36.2%) was higher than the 7.6 to 33% reported in the five most important previous SE epidemiology studies4,13,14,15,16. In addition, the mortality rate in this population was higher than those in most recent studies in developing countries (7.3% in Peru17, 10.5% in India2, 12.1% in Singapore2, 14.8% in Honduras2, 15.9% in China2, 19.8% in Brazil14, 24.8% in Senegal2, 29% in India2, and 26.7% in Thailand2), but not in all (55.4% in Taiwan19).

Our study had important biases that might explain the higher mortality rate we observed. HCFMRP-USP is the largest hospital in northern São Paulo state, serving as a tertiary referral facility for an area comprising more than 1.5 million inhabitants. This may have contributed to inclusion of fewer patients with SE etiologies having a low mortality risk, such as febrile SE (around 50% of cases in pediatric populations under 5 years of age)10,11 idiopathic or cryptogenic SE (representing 5 to 18% of SE cases and with a mortality approaching 0%)10,14,15,20 and alcohol-related SE (2.8% in our sample compared with 8.1 to 25% in other adult studies), which has reported mortality rates of 0 to 10%)2. We employed the 30-minute criterion for SE diagnosis, in contrast to the 5-minute criterion used by some of the recent studies mentioned above. SE mortality has been related to longer duration10,21. SE duration was longer in our sample due to methodological issues (i.e., use of serial EEG instead of continuous EEG monitoring) and to a higher incidence of refractory SE. Also the higher mortality might be related to treatment issues; for example, delay in initiating medical treatment, as the majority of patients had been transferred from other medical facilities, or the lack of medication more effective in SE treatment, such as IV lorazepam.

Excluding the neonatal period, there is evidence that SE mortality increases with age, independent of etiology, ranging from 0 to 8% in children, 14 to 25% in adults, and over 35% in the elderly. In our sample, we observed a similar distribution, but with higher mortality rates at every age: 25.7% in children, 34.7% in adults, and 64.7% in the elderly6,10,13.

In other hospital samples, 30 to 44% of SE patients had a history of previous epilepsy2. In our sample, 52.4% had a history of epilepsy. We believe that this is related to a selection bias that may be unique to our Epilepsy Center in Ribeirão Preto.

**Table 2. Clinical complications and mortality rate.**

<table>
<thead>
<tr>
<th>Complication</th>
<th>N (%)</th>
<th>MR (%)</th>
<th>OR</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial hypotension</td>
<td>20 (19.0%)</td>
<td>70%</td>
<td>5.72</td>
<td>0.002</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>51 (48.6%)</td>
<td>50.9%</td>
<td>3.37</td>
<td>0.006</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>53 (50.5%)</td>
<td>58.5%</td>
<td>8.41</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total</td>
<td>71 (67.6%)</td>
<td>67.6%</td>
<td>16.45</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

MR: mortality rate; OR: odds ratio.

**Table 3. Clinical complications and SE plus.**

<table>
<thead>
<tr>
<th>Complication</th>
<th>N (% total)</th>
<th>SE only</th>
<th>SE plus</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial hypotension</td>
<td>20 (19.0%)</td>
<td>4 (8.2%)</td>
<td>16 (28.6%)</td>
<td>0.012</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>51 (48.6%)</td>
<td>19 (38.8%)</td>
<td>32 (57.1%)</td>
<td>0.079</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>53 (50.5%)</td>
<td>11 (22.4%)</td>
<td>42 (75.0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total</td>
<td>71 (67.6%)</td>
<td>24 (49.0%)</td>
<td>47 (83.9%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

SE: status epilepticus.
One of the best prognostic factors of SE is etiology, and the highest mortality rates are observed in patients with acute symptomatic or progressive symptomatic etiologies. Mortality rates in acute symptomatic SE range from 27 to 34%3,4,10,11,29, which are lower than our findings (53%). Other etiologies, such as febrile SE, are associated with lower mortality rates, from 0 to 3%6,10,11,14. In our sample, febrile SE also had a 0% mortality rate.

In previously epileptic individuals, the predominant causes of SE are noncompliance to treatment or change AED therapy, associated with 20 to 55% of cases. Mortality rates in these patients are low, ranging from 0 to 6%6,14,18,20. In our sample, AED noncompliance, withdrawal, or reduction was observed in 19.6% (43.6% of previously epileptic individuals), and the mortality rate in this group was 11.5% (n = 3). Two deaths were related to cardiorespiratory arrest during SE treatment.

Seizure duration was associated with a increased mortality in several studies6,20,23, but there is no consensus in this finding10,18. We were not able to correlate SE duration with mortality. SE duration was longer in our sample than in others, mainly due to a high incidence of FCS with electroencephalographic SE after control of clinical seizures (subtle SE). As continuous EEG was not available, it was difficult to determine when seizures were controlled.

The reported incidence of refractory SE is 9 to 38%, and mortality in that group is generally higher than in other SE patients, from 16 to 100%24. The incidence (36.2%) and mortality rate (57.9%) of refractory SE in our sample were similar to those in other studies.

The presence and severity of medical comorbidities is associated with a poor prognosis in SE, and can be related to seizure duration, SE etiology, and medical treatment. As medical complications can be related to longer SE duration, more aggressive and prompt medical treatment may be the most effective way to prevent the development of complications. In this sample, severe medical complications were described in 67.6% of patients, a higher incidence than other studies20,25. This was the only independent prognostic factor in multivariate analysis. Yaffe and Lowenstein26 reported a higher survival rate among refractory SE patients without medical complications. Respiratory insufficiency with orotracheal intubation was associated with a high mortality rate in SE27. Occurrence of medical complications, such as arterial hypotension, multiple organ failure, and cardiac arrhythmias, was associated with high mortality in univariate analysis, but not in multivariate analysis22.

EEG is essential for SE diagnosis, especially in nonconvulsive or subtle SE, and to guide its treatment, but its relevance for SE prognosis is not clear2. Of the different ictal EEG patterns, only PLED has been associated with increased mortality28,29, but a number of studies failed to find an association of EEG patterns with prognosis and mortality2. Our data found no association between EEG patterns and mortality. In our sample, PLED was related to a higher mortality rate, but this finding was associated with a higher prevalence of PLED in elderly patients.

In conclusion, this prospective study, conducted in a Brazilian University Hospital, found an SE-related mortality rate (36.2%), which is higher than that reported by most previous studies. Mortality was independently associated with medical complications that occurred during hospitalization.

References


